Avalo Therapeutics (AVTX) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$1.92
- EPS estimate
- −$1.40
- EPS surprise
- −36.93%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 7, 2025
Avalo Therapeutics reported Q2 2025 results on August 7, 2025. The company posted a loss of $1.92 per share, wider than the estimated loss of $1.40, a miss of 36.93%. No revenue was reported for the quarter and none was estimated. In Q1 2025 the loss was $1.25 per share.
Losses run through almost the entire table: 19 of the last 20 quarters show one. The only profit was Q3 2022, at $81.60 per share, on revenue of $14.9 million, the highest in the table. Per-share figures before 2024 are on a far larger scale, with losses of several hundred dollars per share, while 2025 losses are below $2.50. Such steps usually reflect changes in share count rather than in results, so per-share figures across those periods are not directly comparable. Revenue has been small and irregular. Over the last 20 quarters, Avalo beat the EPS estimate six times and missed 14 times.
The newest row in the table dates from August 2025, so later results have not yet been added here. In past years, Q3 results came in early November. The next row will show whether quarterly losses stay in the range of the last four quarters.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 7, 2025 | −$1.40 | −$1.92 | −36.93% | $0.00 | SEC |
| Q1 2025 | May 12, 2025 | −$1.33 | −$1.25 | +6.16% | $0.00 | SEC |
| Q4 2024 | Mar 20, 2025 | −$0.17 | −$2.30 | −1266.61% | $200,000.00 | SEC |
| Q3 2024 | Nov 7, 2024 | −$1.19 | −$2.83 | −137.82% | $249,000.00 | SEC |
| Q2 2024 | Aug 12, 2024 | −$6.70 | −$14.07 | −110.00% | $0.00 | SEC |
| Q1 2024 | May 13, 2024 | −$1.18 | −$141.00 | −11849.15% | $0.00 | SEC |
| Q4 2023 | Mar 29, 2024 | −$4.80 | −$10.10 | −110.42% | $574,000.00 | SEC |
| Q3 2023 | Nov 9, 2023 | −$264.00 | −$26.40 | +90.00% | $236,000.00 | SEC |
| Q2 2023 | Aug 3, 2023 | −$192.00 | −$141.60 | +26.25% | $643,000.00 | SEC |
| Q1 2023 | May 4, 2023 | −$232.80 | −$204.00 | +12.37% | $475,000.00 | SEC |
| Q4 2022 | Mar 29, 2023 | −$176.00 | −$237.60 | −35.00% | $901,000.00 | SEC |
| Q3 2022 | Nov 7, 2022 | −$210.60 | $81.60 | +138.75% | $14.9M | SEC |
| Q2 2022 | Aug 4, 2022 | −$424.80 | −$331.20 | +22.03% | $1.0M | SEC |
| Q1 2022 | May 5, 2022 | −$360.00 | −$576.00 | −60.00% | $1.2M | SEC |
| Q4 2021 | Mar 2, 2022 | −$426.24 | −$460.80 | −8.11% | $198,000.00 | SEC |
| Q3 2021 | Nov 9, 2021 | −$483.84 | −$489.60 | −1.19% | $1.4M | SEC |
| Q2 2021 | Aug 2, 2021 | −$480.00 | −$518.40 | −8.00% | $3.4M | SEC |
| Q1 2021 | May 13, 2021 | −$480.00 | −$921.60 | −92.00% | $473,000.00 | SEC |
| Q4 2020 | Mar 8, 2021 | −$432.00 | −$460.80 | −6.67% | $1.5M | SEC |
| Q3 2020 | Nov 9, 2020 | −$273.60 | −$460.80 | −68.42% | $1.1M | SEC |
Quarterly revenue
Frequently asked questions
When did Avalo Therapeutics (AVTX) last report earnings?
Avalo Therapeutics last reported on Aug 7, 2025, covering fiscal Q2 2025.
Did AVTX beat earnings estimates?
No. Avalo Therapeutics reported EPS of −$1.92 for Q2 2025 against a −$1.40 estimate — a 36.93% miss.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.